Sherry Pierce

8.2k total citations · 1 hit paper
131 papers, 4.5k citations indexed

About

Sherry Pierce is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sherry Pierce has authored 131 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Hematology, 69 papers in Genetics and 33 papers in Molecular Biology. Recurrent topics in Sherry Pierce's work include Acute Myeloid Leukemia Research (89 papers), Chronic Myeloid Leukemia Treatments (50 papers) and Chronic Lymphocytic Leukemia Research (37 papers). Sherry Pierce is often cited by papers focused on Acute Myeloid Leukemia Research (89 papers), Chronic Myeloid Leukemia Treatments (50 papers) and Chronic Lymphocytic Leukemia Research (37 papers). Sherry Pierce collaborates with scholars based in United States, Japan and Lebanon. Sherry Pierce's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Farhad Ravandi, Elihu H. Estey, Susan O’Brien, Stefan Faderl, Elias Jabbour, Gautam Borthakur and William G. Wierda and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sherry Pierce

124 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

2013 539 citations Carlos E. Bueso‐Ramos, Sherry Pierce et al. Leukemia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sherry Pierce United States	36	3.5k	1.8k	1.3k	971	897	131	4.5k
Ellen K. Ritchie United States	30	2.4k 0.7×	1.4k 0.8×	1.2k 0.9×	736 0.8×	678 0.8×	172	3.6k
Carlos Graux Belgium	27	2.2k 0.6×	1.1k 0.6×	581 0.4×	1.4k 1.4×	980 1.1×	91	3.6k
Norbert Gattermann Germany	26	3.6k 1.0×	1.7k 1.0×	1.6k 1.2×	672 0.7×	439 0.5×	55	4.5k
Nicoletta Testoni Italy	35	3.7k 1.1×	1.5k 0.8×	1.9k 1.4×	676 0.7×	744 0.8×	187	4.4k
Bart L. Scott United States	35	3.8k 1.1×	1.0k 0.6×	1.6k 1.2×	1.0k 1.1×	509 0.6×	169	4.3k
H. Kantarjian United States	29	2.4k 0.7×	995 0.6×	2.1k 1.6×	781 0.8×	637 0.7×	120	3.9k
Detlef Haase Germany	23	2.4k 0.7×	1.0k 0.6×	1.1k 0.8×	545 0.6×	346 0.4×	101	3.1k
Maria Concetta Petti Italy	32	2.9k 0.8×	2.0k 1.1×	811 0.6×	698 0.7×	625 0.7×	112	3.7k
Stefan Faderl United States	26	2.0k 0.6×	1.2k 0.7×	1.7k 1.3×	519 0.5×	548 0.6×	115	3.6k
Renato Bassan Italy	32	2.4k 0.7×	664 0.4×	983 0.7×	2.1k 2.2×	1.2k 1.3×	164	4.2k

Countries citing papers authored by Sherry Pierce

Since Specialization

Citations

This map shows the geographic impact of Sherry Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Pierce more than expected).

Fields of papers citing papers by Sherry Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Pierce. The network helps show where Sherry Pierce may publish in the future.

Co-authorship network of co-authors of Sherry Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry Pierce. A scholar is included among the top collaborators of Sherry Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry Pierce. Sherry Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DiNardo, Courtney D., Kelly S. Chien, Danielle Hammond, et al.. (2025). A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia. HemaSphere. 9(10). e70214–e70214.

Senapati, Jayastu, H. Kantarjian, Edward Ayoub, et al.. (2024). Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up. Blood. 144(Supplement 1). 1513–1513. 1 indexed citations

Senapati, Jayastu, Farhad Ravandi, Tapan M. Kadia, et al.. (2024). Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood. 144(Supplement 1). 2903–2903.

Abbas, Hussein A., Hanxiao Sun, Sherry Pierce, et al.. (2022). Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances. 7(5). 828–831.

Venugopal, Sangeetha, Mahran Shoukier, Marina Konopleva, et al.. (2021). Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy. Cancer. 127(19). 3541–3551. 43 indexed citations

Sasaki, Koji, Tapan M. Kadia, Kebede H. Begna, et al.. (2021). Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology. 97(1). 68–78. 29 indexed citations

Samra, Bachar, Guillaume Richard‐Carpentier, Tapan M. Kadia, et al.. (2020). Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer Journal. 10(5). 47–47. 17 indexed citations

Kantarjian, Hagop M., Courtney D. DiNardo, Graciela M. Nogueras‐González, et al.. (2018). Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 124(12). 2534–2540. 20 indexed citations

Bose, Prithviraj, Naveen Pemmaraju, Kurt Schroeder, et al.. (2017). Phase 2 Study of Pracinostat in Combination with Ruxolitinib in Patients (pts) with Myelofibrosis (MF). Blood. 130. 1632–1632. 2 indexed citations

10.

Sasaki, Koji, Elias Jabbour, Jörge E. Cortes, et al.. (2016). Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clinical Lymphoma Myeloma & Leukemia. 16(11). 616–624. 11 indexed citations

11.

Almeida, Luís Eduardo, et al.. (2016). Effects of oral contraceptives on the prevalence of alveolar osteitis after mandibular third molar surgery: a retrospective study. International Journal of Oral and Maxillofacial Surgery. 45(10). 1299–1302. 15 indexed citations

12.

Mattiuzzi, Gloria, Musa Yılmaz, Hagop M. Kantarjian, et al.. (2015). Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. Journal of Infection and Chemotherapy. 21(9). 663–667. 8 indexed citations

13.

Daver, Naval, Jörge E. Cortes, Kate J. Newberry, et al.. (2015). Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica. 100(8). 1058–63. 53 indexed citations

14.

Kantarjian, Hagop M., Deborah A. Thomas, Farhad Ravandi, et al.. (2010). Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 116(24). 5568–5574. 85 indexed citations

15.

Thomas, Deborah A., Susan O’Brien, Stefan Faderl, et al.. (2010). Anthracycline dose intensification in adult acute lymphoblastic leukemia. Cancer. 116(19). 4580–4589. 12 indexed citations

16.

Faderl, Stefan, Zeev Estrov, Sherry Pierce, et al.. (2009). Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. International Journal of Hematology. 89(4). 489–496. 39 indexed citations

17.

Tsimberidou, Apostolia M., Elihu H. Estey, Sijin Wen, et al.. (2008). The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromes. Cancer. 113(7). 1605–1613. 107 indexed citations

18.

Garcia‐Manero, Guillermo, J. Shan, S. Faderl, et al.. (2007). A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 22(3). 538–543. 222 indexed citations

19.

Kantarjian, Hagop M., Miloslav Beran, Jörge E. Cortes, et al.. (2006). Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 106(5). 1099–1109. 75 indexed citations

20.

Kantarjian, Hagop M., Susan O’Brien, Terry Smith, et al.. (1994). Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen. British Journal of Haematology. 88(1). 94–100. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact